FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385665941> ?p ?o ?g. }

• W4385665941 endingPage "e61150fb" @default.
• W4385665941 startingPage "e61150fb" @default.
• W4385665941 abstract "Background: Patients (pts) with acute myeloid leukemia (AML) and FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)+ or FLT3 mutations face poor outcomes. The randomized, double-blind, placebo-controlled, phase 3 QuANTUM-First (NCT02668653) study evaluated the novel, highly potent, and selective type II FLT3 inhibitor quizartinib (Quiz) with standard chemotherapy in pts with FLT3-ITD+ newly diagnosed AML (ndAML). Quiz plus standard intensive induction, consolidation including allogeneic hematopoietic cell transplantation (allo-HCT) in first complete remission (CR1), followed by single-agent continuation therapy (Tx) for up to 3 years (y) significantly improved overall survival (OS). Aims: We evaluated 1) the impact of allo-HCT in CR1 and the interrelationship with Quiz on clinical results and 2) the association between FLT3-ITD minimal residual disease (MRD) pre‒allo-HCT and OS. Methods: Patients aged 18-75 y with ndAML were centrally screened for FLT3-ITD before starting standard induction Tx. Pts were randomized to Quiz (40 mg/d, on days 8-21) or placebo (PBO) and stratified by region (North/South America, Europe, and Asia/other regions), age (<60 y, ≥60 y), and white blood cell (WBC; <40×109/L, ≥40×109/L) at diagnosis. Pts achieving complete remission (CR) or CR with incomplete hematologic recovery (CRi) received up to 4 cycles of high-dose cytarabine plus Quiz (40 mg/d) or PBO and/or allo-HCT followed by up to 3 y of Quiz continuation Tx (30-60 mg/d) or PBO. The primary endpoint was OS. We assessed the impact of allo-HCT in CR1 on OS as a time-dependent covariable in multivariable regression analyses. P values were not adjusted for multiplicity. Results: In QuANTUM-First, 539 pts were randomized to Quiz (n=268) or PBO (n=271). The median age was 56 y (range, 20-75 y). There were 294 (54.5%) women and 245 (45.5%) men. Of the 539 randomized patients, 147 pts (54.9%) on Quiz and 150 (55.4%) on PBO achieved CR whereas 45 (16.8%) on Quiz and 26 (9.6%) on PBO achieved CRi after induction. Among pts who achieved CR (Quiz, n=147; PBO, n=150), 84 (57.1%) on Quiz and 73 (48.7%) on PBO underwent allo-HCT in CR1, predominantly with grafts from unrelated donors (49.7%), followed by siblings (32.5%) and other related donors (17.8%). The median time to allo-HCT in CR1 was 3.5 months in Quiz pts and 3.3 months in PBO pts. After completion of allo-HCT, 61 pts (72.6%) on Quiz and 36 (49.3%) on PBO started 3 y of continuation Tx. Another 115 allo-HCTs were performed outside CR1 (Quiz, n=60; PBO, n=55). A multivariable extended Cox regression was conducted in all randomized pts, stratified by region, age, and WBC, including allo-HCT in CR1 as time dependent and adjusted for FLT3-ITD variant allele frequency and sex. This analysis revealed Quiz treatment (hazard ratio [HR], 0.770; 95% CI, 0.609-0.973; P = 0.0284) and allo-HCT in CR1 (HR, 0.424; 95% CI, 0.301-0.597; P < 0.0001) as favorable factors to OS (Fig. 1). Simon-Makuch plot, used to analyze time-dependent effect of allo-HCT in CR1 on OS, showed that CR pts on Quiz had longer OS regardless of undergoing allo-HCT in CR1 or not (Fig. 2). Kaplan-Meier plot of OS in pts undergoing allo-HCT in CR1 by latest pre–allo-HCT FLT3-ITD MRD status (cutoff 10−4), showed longer OS with Quiz vs PBO particularly in pts with pre–allo-HCT MRD+ status (Fig. 3). Summary/Conclusion: Pts on Quiz had longer OS than pts on PBO, irrespective of allo-HCT in CR1. Pts on Quiz who underwent allo-HCT in CR1 had longer OS than pts on PBO, irrespective of pre–allo-HCT MRD status.Keywords: AML, flt3 inhibitor, Allogeneic hematopoietic stem cell transplant, Flt3-ITD" @default.
• W4385665941 created "2023-08-09" @default.
• W4385665941 creator A5000436961 @default.
• W4385665941 creator A5003682435 @default.
• W4385665941 creator A5007141472 @default.
• W4385665941 creator A5011742331 @default.
• W4385665941 creator A5015140142 @default.
• W4385665941 creator A5016023842 @default.
• W4385665941 creator A5020675217 @default.
• W4385665941 creator A5032116716 @default.
• W4385665941 creator A5037460404 @default.
• W4385665941 creator A5045802079 @default.
• W4385665941 creator A5050556099 @default.
• W4385665941 creator A5053949970 @default.
• W4385665941 creator A5055206475 @default.
• W4385665941 creator A5055740968 @default.
• W4385665941 creator A5056530357 @default.
• W4385665941 creator A5062641058 @default.
• W4385665941 creator A5064148484 @default.
• W4385665941 creator A5067783564 @default.
• W4385665941 creator A5074468239 @default.
• W4385665941 creator A5080855457 @default.
• W4385665941 creator A5086214965 @default.
• W4385665941 date "2023-08-01" @default.
• W4385665941 modified "2023-10-01" @default.
• W4385665941 title "S137: IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN FIRST COMPLETE REMISSION PLUS FLT3 INHIBITION WITH QUIZARTINIB IN ACUTE MYELOID LEUKEMIA WITH FLT3-ITD: RESULTS FROM QUANTUM-FIRST" @default.
• W4385665941 doi "https://doi.org/10.1097/01.hs9.0000967460.61150.fb" @default.
• W4385665941 hasPublicationYear "2023" @default.
• W4385665941 type Work @default.
• W4385665941 citedByCount "0" @default.
• W4385665941 crossrefType "journal-article" @default.
• W4385665941 hasAuthorship W4385665941A5000436961 @default.
• W4385665941 hasAuthorship W4385665941A5003682435 @default.
• W4385665941 hasAuthorship W4385665941A5007141472 @default.
• W4385665941 hasAuthorship W4385665941A5011742331 @default.
• W4385665941 hasAuthorship W4385665941A5015140142 @default.
• W4385665941 hasAuthorship W4385665941A5016023842 @default.
• W4385665941 hasAuthorship W4385665941A5020675217 @default.
• W4385665941 hasAuthorship W4385665941A5032116716 @default.
• W4385665941 hasAuthorship W4385665941A5037460404 @default.
• W4385665941 hasAuthorship W4385665941A5045802079 @default.
• W4385665941 hasAuthorship W4385665941A5050556099 @default.
• W4385665941 hasAuthorship W4385665941A5053949970 @default.
• W4385665941 hasAuthorship W4385665941A5055206475 @default.
• W4385665941 hasAuthorship W4385665941A5055740968 @default.
• W4385665941 hasAuthorship W4385665941A5056530357 @default.
• W4385665941 hasAuthorship W4385665941A5062641058 @default.
• W4385665941 hasAuthorship W4385665941A5064148484 @default.
• W4385665941 hasAuthorship W4385665941A5067783564 @default.
• W4385665941 hasAuthorship W4385665941A5074468239 @default.
• W4385665941 hasAuthorship W4385665941A5080855457 @default.
• W4385665941 hasAuthorship W4385665941A5086214965 @default.
• W4385665941 hasBestOaLocation W43856659411 @default.
• W4385665941 hasConcept C126322002 @default.
• W4385665941 hasConcept C142724271 @default.
• W4385665941 hasConcept C143998085 @default.
• W4385665941 hasConcept C168563851 @default.
• W4385665941 hasConcept C203092338 @default.
• W4385665941 hasConcept C204787440 @default.
• W4385665941 hasConcept C27081682 @default.
• W4385665941 hasConcept C2776611710 @default.
• W4385665941 hasConcept C2776694085 @default.
• W4385665941 hasConcept C2777408962 @default.
• W4385665941 hasConcept C2778041864 @default.
• W4385665941 hasConcept C2778461978 @default.
• W4385665941 hasConcept C2778729363 @default.
• W4385665941 hasConcept C2779823535 @default.
• W4385665941 hasConcept C2911091166 @default.
• W4385665941 hasConcept C71924100 @default.
• W4385665941 hasConcept C90924648 @default.
• W4385665941 hasConceptScore W4385665941C126322002 @default.
• W4385665941 hasConceptScore W4385665941C142724271 @default.
• W4385665941 hasConceptScore W4385665941C143998085 @default.
• W4385665941 hasConceptScore W4385665941C168563851 @default.
• W4385665941 hasConceptScore W4385665941C203092338 @default.
• W4385665941 hasConceptScore W4385665941C204787440 @default.
• W4385665941 hasConceptScore W4385665941C27081682 @default.
• W4385665941 hasConceptScore W4385665941C2776611710 @default.
• W4385665941 hasConceptScore W4385665941C2776694085 @default.
• W4385665941 hasConceptScore W4385665941C2777408962 @default.
• W4385665941 hasConceptScore W4385665941C2778041864 @default.
• W4385665941 hasConceptScore W4385665941C2778461978 @default.
• W4385665941 hasConceptScore W4385665941C2778729363 @default.
• W4385665941 hasConceptScore W4385665941C2779823535 @default.
• W4385665941 hasConceptScore W4385665941C2911091166 @default.
• W4385665941 hasConceptScore W4385665941C71924100 @default.
• W4385665941 hasConceptScore W4385665941C90924648 @default.
• W4385665941 hasIssue "S3" @default.
• W4385665941 hasLocation W43856659411 @default.
• W4385665941 hasLocation W43856659412 @default.
• W4385665941 hasOpenAccess W4385665941 @default.
• W4385665941 hasPrimaryLocation W43856659411 @default.
• W4385665941 hasRelatedWork W1583871986 @default.
• W4385665941 hasRelatedWork W2079966689 @default.
• W4385665941 hasRelatedWork W2186865501 @default.
• W4385665941 hasRelatedWork W2440552357 @default.
• W4385665941 hasRelatedWork W2461234028 @default.
• W4385665941 hasRelatedWork W2488190774 @default.

• next